Abbott's Receives FDA Approval For Esprit BTK Everolimus Eluting Resorbable Scaffold System
Abbott's Receives FDA Approval For Esprit BTK Everolimus Eluting Resorbable Scaffold System
雅培的 Esprit BTK Everolimus 洗脫可吸收腳手架系統獲得 FDA 批准
- More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options
- The first-of-its-kind Esprit BTK Everolimus Eluting Resorbable Scaffold dissolves over time after it has opened blocked arteries below the knee (BTK)
- The Esprit BTK System is a dissolving stent that offers the possibility of better outcomes for people with the most severe form of PAD
- 美國有超過2000萬人患有外周動脈疾病（PAD），但治療選擇有限
- 首款 Esprit BTK Everolimus Eluting 可吸收支架在打開膝蓋以下阻塞動脈 (BTK) 後會隨着時間的推移而溶解
- Esprit BTK 系統是一種溶解性支架，可爲最嚴重的 PAD 患者提供更好的治療效果
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。